Areas of Research

Epigenetic Regulation of Immune Cell Function in Disease

Nanotherapy Targeting Immune Signaling Pathways and Epigenetic Targets

Next Generation Sequencing

Who We Are

The IECT Labs, led by Dr. Katherine Gallagher, works at the intersection of immunology, biomedical research, and cardiovascular medicine. The fields of immunotherapy and epigenetics have grown tremendously over the previous decade.

Although these areas have been more well studied in cancer, they are relevant for cardiovascular disease and can be specifically targeted using nanocarriers and other technology to modulate inflammation and other pathologic processes in cardiovascular disease and to aid in tissue repair processes.

Our group aims to translate our findings identifying important epigenetic pathways into therapeutic cell specific therapy for the treatment of patients with cardiovascular and cardiometabolic diseases.

11/14/22  Barmada and Gallagher Labs

Latest Publications

The Histone Methyltransferase, Setdb2, Modulates Macrophage Phenotype and Uric Acid Production in Normal and Diabetic Wound Repair.

Kimball AS, Davis FM, denDekker A, Joshi A, Schaller M, Bermick J, Burant C, Obi A, Nycz D. Robinson S, Allen R, Lukacs N, Henke PK, Moore BB, Kunkel SL, Gallagher KA.

Immunity 51(2): 258-271, 2019. 31350176


Coronavirus induces diabetic macrophage mediated inflammation via SETDB2.

Melvin WJ, Audu CO, Davis FM, Sharma SB, Joshi A, denDekker AD, Wolf S, Barrett E, Mangum K, Zhou X, Bame M, Ruan A, Obi, AT, Kunkel SL, Moore BB, Gallagher KA.

PNAS. 2021. Sept 21; 118(38):e2101071118. 34479991


Are You a Trainee Looking to Join the Gallagher Lab at U-M?

We are currently looking for new lab members! Master's, doctoral, and post-doctoral students are encouraged to apply.